Interestingly, these findings seem to contradict previous reports suggesting that TLR4 inhibition by triptolide can enhance the sensitivity of pancreatic cancer cells to gemcitabine by inhibiting the TLR4/NF-κB signaling [112]. The gene discussed is TLR4; the disease is familial pancreatic carcinoma.